Industrial, Manufacturing & Heavy Industry Market News

ECMO Machine Market expected to reach USD 305.3 Million by 2021

Industrial Market Research

The extracorporeal membrane oxygenation (ECMO) machine market is poised to reach USD 305.3 Million by 2021

- Advertising -

This report studies the global ECMO machine market for the forecast period of 2016 to 2021. This market is expected to reach USD 305.3 Million by 2021 from USD 247.2 Million in 2016, at a CAGR of 4.3%. A number of factors such as the growing cardiovascular and respiratory diseases, rising adoption of ECMO as a bridge to heart & lung transplantation, growing number of ECMO centers, conferences and training programs to increase awareness, and technological advancements are the significant factors driving the growth of this market. In addition, the growing aging population and the number of people suffering from cardiopulmonary diseases in populous countries such as India and China are factors that are expected to offer significant growth opportunities for ECMO systems.

- Advertising -

The global market is segmented on the basis of modality, applications, and regions.

Based on the modality, the global market is segmented into venoarterial (VA), venovenous (VV), and arteriovenous (AV). The venovenous (VV) segment is estimated to account for the largest share of the global market in 2016, and venoarterial (VA) segment is projected to grow at the highest CAGR in the forecast period.

Based on application, the global market is segmented into Respiratory, Cardiac, and Extracorporeal Cardiopulmonary Resuscitation (ECPR). The respiratory segment is estimated to account for the largest share of the market in 2016. The large share of this segment can be attributed to factors such as rising incidence of respiratory failure, lung cancer, and lung transplants, and increasing adoption of ECMO.

Download Brochure: www.marketsandmarkets.com/pdfdownload.asp?id=255167654   

A number of key players are competing against each other to expand their existing customer base. Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.) are the top three players of the extracorporeal membrane oxygenation (ECMO) machine market. These players jointly accounted for a share of 65% to 70% of the total ECMO machine market in 2015.

Getinge Group is the largest player in the global market. The company offers its ECMO products under its Maquet brand. The firm develops and commercializes ECMO products and is one of the leading manufacturers of heart-lung machines, oxygenators, pumps, catheters, cannulae, and other accessories. The company’s business segments include Medical Systems, Extended Care, and Infection Control. The Medical Systems segment offers a wide range of ECMO devices. The company also develops innovative products such as CARDIOHELP system which is a portable heart-lung support system in the market. Moreover, in September 2015, the company partnered with iMDsoft GmbH (Germany) to offer clinical information systems to reduce the documentation process time of heart-lung machines, blood/gas monitors, and heater-cooler units. The firm also remains committed to investing ~4.2% of its revenue in R&D activities; in 2015, the company invested USD 150 million on R&D. The company has succeeded in creating a strong foothold owing to its long-term presence in the market, a wide geographic presence, strong sales force, and innovative product offerings.

News From

MarketsandMarkets™ - Business ResearchMarketsandMarkets™
Category: Market Research Publishers and RetailersCompany about: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
This email address is being protected from spambots. You need JavaScript enabled to view it.